Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
901 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04426825 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT02108652 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | completed | Phase 2 | 310 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT02951767 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | completed | Phase 2 | 119 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT04158583 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Hoffmann-La RocheINDUSTRY | 5 | Mar 4, 2024 | clinicaltrials |
| NCT02393924 | Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study(ESTHER) | completed | — | 311 | Hoffmann-La RocheINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04857138 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 80 | Hoffmann-La RocheINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT04657302 | A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03840200 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 5 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | terminated | Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02005471 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)(MURANO) | completed | Phase 3 | 389 | Hoffmann-La RocheINDUSTRY | 20 | Oct 17, 2023 | clinicaltrials |
| NCT04404140 | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 4 | Oct 17, 2023 | clinicaltrials |
| NCT02611323 | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 133 | Hoffmann-La RocheINDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT03559647 | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | completed | — | 358 | Hoffmann-La RocheINDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03695380 | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | completed | Phase 1 | 77 | Hoffmann-La RocheINDUSTRY | 3 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05129280 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | terminated | Phase 1 | 23 | Hoffmann-La RocheINDUSTRY | 6 | Aug 4, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT02663232 | Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma | completed | — | 264 | Hoffmann-La RocheINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection(IMvigor010) | terminated | Phase 3 | 809 | Hoffmann-La RocheINDUSTRY | 24 | Jun 18, 2023 | clinicaltrials |
| NCT04751162 | A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.(Lupa-01) | completed | — | 71 | Hoffmann-La RocheINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04341259 | A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. | completed | Phase 1 | 12 | Hoffmann-La RocheINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT03084939 | Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 351 | Hoffmann-La RocheINDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02536664 | Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants | completed | — | 505 | Hoffmann-La RocheINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01164891 | A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT03321695 | A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina | completed | — | 44 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | completed | — | 13 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials